{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:05:13Z","timestamp":1790546713498,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10-11","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by hypotonia, progressive muscle weakness, and wasting. Onasemnogene abeparvovec (Zolgensma<jats:sup>\u00ae<\/jats:sup>) is a novel gene therapy medicine, FDA-approved in May 2019 for the treatment of SMA. This study aimed to describe Qatari experience with onasemnogene abeparvovec by reviewing the clinical outcomes of 9 SMA children (7 SMA type 1 and 2 with SMA type 2) aged 4\u201223 months treated between November 2019 and July 2020. Children &lt;2 years with 5q SMA with a bi-allelic mutation in the <jats:italic>SMN1<\/jats:italic> gene were eligible for gene therapy. Liver function (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and total bilirubin), platelet count, coagulation profile, troponin-I levels, and motor scores (Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders [CHOP INTEND]), were regularly monitored following gene therapy. All patients experienced elevated AST or ALT, two experienced high prothrombin time, and one experienced elevated bilirubin; all of these patients were asymptomatic. Furthermore, one event of vomiting after infusion was reported in one patient. Significant improvements in CHOP INTEND scores were observed following therapy. This study describes the short-term outcomes and safety of onasemnogene abeparvovec, which is well tolerated and shows promise for early efficacy.<\/jats:p>","DOI":"10.1038\/s41434-021-00273-7","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T02:02:49Z","timestamp":1626660169000},"page":"676-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Gene therapy for spinal muscular atrophy: the Qatari experience"],"prefix":"10.1038","volume":"28","author":[{"given":"Hossamaldein Gaber","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Fawzi","family":"Elsaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Babiker","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud I. A.","family":"Abeidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-7159","authenticated-orcid":false,"given":"Azhar Othman","family":"Al Rawwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Elshafey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer","family":"Almulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"El-Akouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Almulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Al-Mesaifri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora","family":"Shahbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Al-Mureikhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Alsulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Alkaabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-7738","authenticated-orcid":false,"given":"Tawfeg","family":"Ben-Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"273_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365.","journal-title":"Cell."},{"key":"273_CR2","unstructured":"Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews\u00ae. Seattle: University of Washington; 1993."},{"key":"273_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12:124.","journal-title":"Orphanet J Rare Dis."},{"key":"273_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5144\/0256-4947.1992.67","volume":"12","author":"S Al-Rajeh","year":"1992","unstructured":"Al-Rajeh S, Bademosi O, Gascon GG, Stumpf D. Werdnig Hoffman\u2019s disease (spinal muscular atrophy type I): A clinical study of 25 Saudi nationals in Al-Khobar. Ann Saudi Med. 1992;12:67\u201371.","journal-title":"Ann Saudi Med."},{"key":"273_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000110316","volume":"12","author":"S al Rajeh","year":"1993","unstructured":"al Rajeh S, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freihi H, et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology. 1993;12:164\u201378.","journal-title":"Neuroepidemiology."},{"key":"273_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000083334","volume":"8","author":"A Rajab","year":"2005","unstructured":"Rajab A, Bappal B, Al-Shaikh H, Al-Khusaibi S, Mohammed AJ. Common autosomal recessive diseases in Oman derived from a hospital-based registry. Community Genet. 2005;8:27\u201330.","journal-title":"Community Genet."},{"key":"273_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jmg.32.1.7","volume":"32","author":"LI al-Gazali","year":"1995","unstructured":"al-Gazali LI, Dawodu AH, Sabarinathan K, Varghese M. The profile of major congenital abnormalities in the United Arab Emirates (UAE) population. J Med Genet. 1995;32:7\u201313.","journal-title":"J Med Genet."},{"key":"273_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejmhg.2011.02.015","volume":"12","author":"RM Shawkya","year":"2011","unstructured":"Shawkya RM, El-Sayedb NS. Clinico-epidemiologic characteristics of spinal muscular atrophy among Egyptians. Egyptian J Med Hum Genet. 2011;12:25\u201330.","journal-title":"Egyptian J Med Hum Genet."},{"key":"273_CR9","first-page":"221","volume":"5","author":"M Al Jumah","year":"2007","unstructured":"Al Jumah M, Majumdar R, Rehana Z, Al Rajeh S, Eyaid W. A pilot study of spinal muscular atrophy carrier screening in Saudi Arabia. J Pediatric Neurol. 2007;5:221\u20134.","journal-title":"J Pediatric Neurol."},{"key":"273_CR10","first-page":"A02200100","volume":"67","author":"SS Albrechtsen","year":"2020","unstructured":"Albrechtsen SS, Born AP, Boesen MS. Nusinersen treatment of spinal muscular atrophy\u2014a systematic review. Dan Med J. 2020;67:A02200100.","journal-title":"Dan Med J."},{"key":"273_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med."},{"key":"273_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","volume":"98","author":"LP Lowes","year":"2019","unstructured":"Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW, McColly M, et al. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39\u201345.","journal-title":"Pediatr Neurol."},{"key":"273_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","volume":"6","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Kolb SJ, Lowes L, Alfano LN, Shell R, Church KR, et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. J Neuromuscul Dis. 2019;6:307\u201317.","journal-title":"J Neuromuscul Dis."},{"key":"273_CR14","doi-asserted-by":"publisher","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","volume":"146","author":"MA Waldrop","year":"2020","unstructured":"Waldrop MA, Karingada C, Storey MA, Powers B, Iammarino MA, Miller NF, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146:e20200729.","journal-title":"Pediatrics."},{"key":"273_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","volume":"8","author":"J Friese","year":"2021","unstructured":"Friese J, Geitmann S, Holzwarth D, Muller N, Sassen R, Baur U, et al. Safety monitoring of gene therapy for spinal muscular atrophy with onasemnogene abeparvovec\u2014a single centre experience. J Neuromuscul Dis. 2021;8:209\u201316.","journal-title":"J Neuromuscul Dis"},{"key":"273_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155\u201361.","journal-title":"Neuromuscul Disord."},{"key":"273_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2020","unstructured":"Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2020;74:560\u20136.","journal-title":"J Hepatol"},{"key":"273_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","volume":"225","author":"AG Feldman","year":"2020","unstructured":"Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252\u20138.e251.","journal-title":"J Pediatr."},{"key":"273_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2020","unstructured":"Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2020;231:265\u20138.","journal-title":"J Pediatr"},{"key":"273_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","volume":"28","author":"J Kirschner","year":"2020","unstructured":"Kirschner J, Butoianu N, Goemans N, Haberlova J, Kostera-Pruszczyk A, Mercuri E, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38\u201343.","journal-title":"Eur J Paediatr Neurol."},{"key":"273_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355\u201368.","journal-title":"Ann Neurol."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00273-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:47Z","timestamp":1684617287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00273-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":21,"journal-issue":{"issue":"10-11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00273-7","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}